Added to YB: 2025-09-25
Pitch date: 2025-09-23
LVTX [bullish]
LAVA Therapeutics N.V.
+10.83%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments.
Market Cap
$45.8M
Pitch Price
$1.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.19
P/E
-2.02
EV/Sales
-0.78
Sector
Biotechnology
Category
special_situation
LVTX: The hottest CVR in town
LVTX CVR: Trading at 25-33¢ vs $23.89 face value from Pfizer/JNJ milestones (1-1.3% of potential). 10yr term, 75% of partnership proceeds to holders. Pfizer advanced asset to Phase 1 (260 patients), JNJ filed IND Oct 2024. $643M Pfizer milestones, $195M JNJ outstanding. Historical 50% Phase 1→2 success rate could trigger payouts exceeding entire CVR cost.
Read full article (9 min)